English
Español
Português
Home
About Us
Overview
Business Model
Milestones
Our Presence
Board of Directors
Committees of Board
Management Team
Corporate Governance Report
Mission, Vision and Values
Environment
Products
Research & Development
Product Development
R & D Capabilities
Infrastructure
Capacities and Capabilities
Regulatory Approvals
Environmental/Social Information
Investor Relations
Overview
Corporate Details
Company Finanicals
Shareholders Information
Shareholders feedback form
Code of Conduct
News and Media
Careers
Contact Us
Sales Offices
Enquiry Form
FAQs
Granules Overview
Corporate Responsibility
Research & Development
News & Media
Who We Are & What We Do
Granules is a world class, large scale manufacturing company partnering with market leaders to offer pharmaceutical products and services. We have a long history as a producer of active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates(PFIs) and finished dosages(FDs).
know more
Our Presence
Granules delivers to more than 300 customers, in over 50 countries, with offices located in:
Europe
United States
India
Latin America
AMEA(ex India/China)
China
know more
Corporate responsibility is an intrinsic and fundamental part of Granules. Our success is driven by how we choose to conduct ourselves, how we maintain the environment we work in and our community.
At Granules we are always looking to reduce our environmental footprint. Our Green Initiatives will not only help the environment, but will lower operating costs and will support endeavor to become a preferred partner.
know more
The commitment of Granules to ethical and lawful business conduct is a fundamental shared value of our Board of Directors, Management and Employees and critical to the Company's success.
know more
Product Development
Our focus on customer service does not start at the begining of our supply chain, but at our labs where we introduce new or improved processes and customized products at every step of our value chain.
know more
R&D Capabilities
Our advanced infrastructure, such as our geometrically scaled down equipment for PFA product development ensures precision and offers cost saving to our customers. We also have a 30 member team dedicated to product development of our finished dosages.
know more
Granules India’s Sales increase 45% to Rs. 186 Cr.; Net Profit up 42%
Granules India’s Net Revenue soars 37%; PBT before non-cash expense jumps 70%
Granules India’s Net Revenue increases 9% due to strong formulation sales
Granules India and Ajinomoto OmniChem to create a strategic Joint Venture in India
Granules India’s Net Profit excluding exceptional items increases 21%; Dividend to be increased by 20%
read more..